ChengDa PharmaCeuticals Co., Ltd. Class A

ChengDa PharmaCeuticals Co., Ltd. Class A

SSZSE:301201
21.16
CNY
-0.54
(-2.49%)
-0.27EPS
4.72BMarket Cap

Total Valuation

CNY

As of September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A carries a market capitalization of 4.72B, placing it among publicly traded companies globally. Its enterprise value stands at 3.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.72B
Enterprise Value3.84B

Share Statistics

As of September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A has 154.71M shares outstanding.

Shares Outstanding154.71M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 9.68, and the price-to-book ratio stands at 2.30.

PS Ratio9.68
PB Ratio2.30
P/TBV Ratio2.34

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 8.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.84B versus a market cap of 4.72B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.05

Financial Position

As of September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A maintains a current ratio of 5.55, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.52, indicating elevated leverage, while an interest coverage ratio of -33.07 demonstrates limited ability to service its debt obligations.

Current Ratio5.55
Quick Ratio4.13
Debt / Equity2.52
Debt / EBITDA-1.43
Interest Coverage-33.07

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A posted a negative return on equity (ROE) of -1.95, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.74, reflecting losses generated across the asset base. The company generates approximately 723,767.25 in revenue per employee across its workforce of 659.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.00 indicates how many times ChengDa PharmaCeuticals Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-1.95
Return on Assets (ROA)-1.74
Revenue Per Employee723,767.25
Employee Count659.00
Inventory Turnover2.00

Taxes

CNY

Over the twelve months ended September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A recorded an income tax benefit of -2.61M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -43.85M and -41.13M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-2.61M

Stock Price Statistics

CNY

As of the close on November 17, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A's stock has declined approximately 57.32% over the past 52 weeks. The 50-day moving average sits at 28.69, while the 200-day moving average is 36.48.

52-Week Price Change-57.32%
50-Day Moving Average28.69
200-Day Moving Average36.48

Income Statement

CNY

Over the twelve months ended September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A generated 476.96M in revenue and converted that into -41.13M in net income, yielding earnings per share of -0.27. EBITDA reached -36.18M, while operating income came in at -4.24M.

Revenue476.96M
Gross Profit157.24M
Operating Income-4.24M
Pretax Income-43.85M
Net Income-41.13M
EBITDA-36.18M
EBIT-36.18M
Earnings Per Share (EPS)-0.27

Balance Sheet

CNY

As of September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A holds 929.89M in cash and equivalents against 51.73M in total debt, resulting in a net debt position of -56.29M. Total book value stands at 2.05B, with working capital of 1.02B providing operational flexibility.

Cash & Cash Equivalents929.89M
Total Debt51.73M
Net Debt-56.29M
Equity (Book Value)2.05B
Book Value Per Share13.26
Working Capital1.02B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-60.85M

Margins

Over the twelve months ended September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A posted a gross margin of 32.97, reflecting its pricing power and cost economics. The operating margin of -0.89 and net profit margin of -8.62 provide insight into operational efficiency.

Gross Margin32.97
Operating Margin-0.89
Pretax Margin-9.19
Profit Margin-8.62
EBITDA Margin-7.59

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A paid dividends of 0.22 per share. The dividend payout ratio of -80.61 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ChengDa PharmaCeuticals Co., Ltd. Class A shareholders.

Dividend Per Share0.22
Payout Ratio-80.61
Shareholder Yield0.84

Stock Splits

ChengDa PharmaCeuticals Co., Ltd. Class A's most recent stock split took place on July 7, 2023 with a 5:8 split ratio.

Last Split Date7/7/2023
Split Ratio5:8

Scores

As of September 30, 2026, ChengDa PharmaCeuticals Co., Ltd. Class A has an Altman Z-Score of 11.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.14